ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ONTAK
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ONTAK Rx

Generic Name and Formulations:
Denileukin diftitox 150mcg/mL; soln for IV infusion after thawing and dilution.

Company:
Eisai Pharmaceuticals

Therapeutic Use:

Indications for ONTAK:

Persistent or recurrent cutaneous T-cell lymphoma in which malignant cells express the CD25 component of the IL-2 receptor.

Adult:

Premedicate with an antihistamine or acetaminophen prior to each infusion. Give by IV infusion over 30–60 minutes. 9 or 18mcg/kg per day for 5 consecutive days every 21 days for 8 cycles.

Children:

Not recommended.

Warnings/Precautions:

Ensure CD25 expression before starting therapy. Have resuscitative equipment available during administration. Permanently discontinue if serious infusion reactions occur. Monitor for signs/symptoms of capillary leak syndrome (hypotension, edema, hypoalbuminemia) and weight gain. Monitor serum albumin levels prior to each treatment course; withhold treatment if serum albumin <3g/dL. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Interleukin 2-diphtheria toxin fusion protein.

Adverse Reactions:

Fever, fatigue, rigors, GI upset, headache, edema, cough, dyspnea, pruritus, rash, hypotension, back pain, myalgia, chest pain, tachycardia, hypoalbuminemia, asthenia, elevated transaminases; capillary leak syndrome (may be fatal), serious infusion reactions, visual impairment (monitor).

Note:

Testing considerations: CD25 expression

How Supplied:

Single-use vials (2mL)—6

Sign Up for Free e-Newsletters

CME Focus